Compare UGRO & AZTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UGRO | AZTR |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | United States | United States |
| Employees | 130 | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8M | 1.9M |
| IPO Year | 2018 | 2023 |
| Metric | UGRO | AZTR |
|---|---|---|
| Price | $2.43 | $0.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 181.8K | ★ 1.6M |
| Earning Date | 01-01-0001 | 06-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5.06 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $40,008,850.00 | N/A |
| Revenue This Year | $98.41 | N/A |
| Revenue Next Year | $23.34 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.11 | $0.14 |
| 52 Week High | $4.50 | $1.40 |
| Indicator | UGRO | AZTR |
|---|---|---|
| Relative Strength Index (RSI) | 56.25 | 40.37 |
| Support Level | $0.28 | $0.15 |
| Resistance Level | $4.50 | $0.32 |
| Average True Range (ATR) | 0.30 | 0.02 |
| MACD | -0.12 | 0.00 |
| Stochastic Oscillator | 20.94 | 51.76 |
Urban-gro Inc operated as an integrated professional services and design-build firm offering architectural, engineering, and construction management solutions to the CEA, industrial, healthcare, and other commercial sectors. The company generated revenue by billing employees time on client projects and provided architectural, engineering, systems procurement and integration, and construction design-build solutions with a single point of accountability. For CEA clients, it developed indoor cultivation facilities for specialty crops, including cannabis and produce such as leafy greens, vegetables, herbs, and berries. Its segments included Equipment Systems (commercial horticulture equipment), Services (design-build services), and Construction Design-Build (general contracting).
Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.